Results 71 to 80 of about 1,442,074 (300)

The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction

eLife, 2016
In response to proteasome dysfunction, mammalian cells upregulate proteasome gene expression by activating Nrf1. Nrf1 is an endoplasmic reticulum-resident transcription factor that is continually retrotranslocated and degraded by the proteasome.
Shun Koizumi, Taro Irie, Shoshiro Hirayama, Yasuyuki Sakurai, Hideki Yashiroda, Isao Naguro, Hidenori Ichijo, Jun Hamazaki, Shigeo Murata   +8 more
doaj   +1 more source

Low Dose Proteasome Inhibition Affects Alternative Splicing

, 2016
Protein degradation by the ubiquitin proteasome system ensures controlled degradation of structural proteins, signaling mediators, and transcription factors.
Silke Meiners (792092), Elke Hammer (443358), Sven Bieler (2058886), Manuela Gesell-Salazar (2058889), Uwe Völker (2058892), Karl Stangl (207195)   +5 more
core   +2 more sources

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition [PDF]

, 2022
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Wallington-Beddoe, Craig T, Creek, Darren J, Pitson, Stuart M, Orlowski, Robert Z, Anderson, Dovile, Powell, Jason A, Li, Manjun, Bennett, Melissa K, Pitman, Melissa R, Toubia, John, Tea, Melinda N, Wang, Paul P-S, Gliddon, Briony L   +12 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Chemical and Biological Mechanisms Relevant to the Rescue of MG-132-Treated Neurons by Cysteine

Antioxidants
Proteasome dysfunctions are observed in many human pathologies. To study their role and potential treatment strategies, models of proteasome inhibition are widely used in biomedical research.
Anna-Katharina Ückert, Ilinca Suciu, Anja Land, Anna-Sophie Spreng, Hannah Welte, Doreen Herzog, Michael Basler, Marcel Leist   +7 more
doaj   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

Molecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna, Jodie Hay, Michael W. Moles, Lucy Clarke, Jennifer Cassels, Alison Sefcick, Alison M. McCaig, Heather G. Jørgensen, Alison M. Michie   +8 more
wiley   +1 more source

Effects of Proteasome Inhibition on Tau Protein

, 2011
The ubiquitin-proteasome system is an important proteolytic pathway implicated in the formation of neurofibrillary tangles from hyperphosphorylated tau, a pathological hallmark of tauopathies such as Alzheimer’s disease.
Cheng, Shuk Yee
core   +1 more source

Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus

Journal of Neuroinflammation, 2012
Background Neuroinflammation and protein accumulation are characteristic hallmarks of both normal aging and age-related neurodegenerative diseases. However, the relationship between these factors in neurodegenerative processes is poorly understood.
Pintado Cristina, Gavilán María P, Gavilán Elena, García-Cuervo Luisa, Gutiérrez Antonia, Vitorica Javier, Castaño Angélica, Ríos Rosa M, Ruano Diego   +8 more
doaj   +1 more source

Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. [PDF]

PLoS ONE, 2013
The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little attention
Tamer B Shabaneh, Sondra L Downey, Ayrton L Goddard, Michael Screen, Marcella M Lucas, Alan Eastman, Alexei F Kisselev   +6 more
doaj   +1 more source